These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 18254239)
1. Binding mode analysis of topoisomerase inhibitors, 6-arylamino-7-chloro-quinazoline-5,8-diones, within the cleavable complex of human topoisomerase I and DNA. Choi I; Kim C; Choi S Arch Pharm Res; 2007 Dec; 30(12):1526-35. PubMed ID: 18254239 [TBL] [Abstract][Full Text] [Related]
2. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334 [TBL] [Abstract][Full Text] [Related]
3. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354 [TBL] [Abstract][Full Text] [Related]
4. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin. Kerrigan JE; Pilch DS Biochemistry; 2001 Aug; 40(33):9792-8. PubMed ID: 11502172 [TBL] [Abstract][Full Text] [Related]
5. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents. Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440 [TBL] [Abstract][Full Text] [Related]
6. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Pommier Y; Kohlhagen G; Kohn KW; Leteurtre F; Wani MC; Wall ME Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8861-5. PubMed ID: 7568032 [TBL] [Abstract][Full Text] [Related]
7. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827 [TBL] [Abstract][Full Text] [Related]
8. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631 [TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. Desai SD; Liu LF; Vazquez-Abad D; D'Arpa P J Biol Chem; 1997 Sep; 272(39):24159-64. PubMed ID: 9305865 [TBL] [Abstract][Full Text] [Related]
10. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. Cushman M; Jayaraman M; Vroman JA; Fukunaga AK; Fox BM; Kohlhagen G; Strumberg D; Pommier Y J Med Chem; 2000 Oct; 43(20):3688-98. PubMed ID: 11020283 [TBL] [Abstract][Full Text] [Related]
11. 6-Arylamino-7-chloro-quinazoline-5,8-diones as novel cytotoxic and DNA topoisomerase inhibitory agents. Park HJ; Kim YS; Kim JS; Lee EJ; Yi YJ; Hwang HJ; Suh ME; Ryu CK; Lee SK Bioorg Med Chem Lett; 2004 Jul; 14(13):3385-8. PubMed ID: 15177438 [TBL] [Abstract][Full Text] [Related]
12. DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. Pommier Y; Jenkins J; Kohlhagen G; Leteurtre F Mutat Res; 1995 Sep; 337(2):135-45. PubMed ID: 7565862 [TBL] [Abstract][Full Text] [Related]
13. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Valenti M; Nieves-Neira W; Kohlhagen G; Kohn KW; Wall ME; Wani MC; Pommier Y Mol Pharmacol; 1997 Jul; 52(1):82-7. PubMed ID: 9224816 [TBL] [Abstract][Full Text] [Related]
14. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666 [TBL] [Abstract][Full Text] [Related]
15. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542 [TBL] [Abstract][Full Text] [Related]
16. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Wu J; Liu LF Nucleic Acids Res; 1997 Nov; 25(21):4181-6. PubMed ID: 9336444 [TBL] [Abstract][Full Text] [Related]
17. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode. Cinelli MA; Morrell AE; Dexheimer TS; Agama K; Agrawal S; Pommier Y; Cushman M Bioorg Med Chem; 2010 Aug; 18(15):5535-52. PubMed ID: 20630766 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives. Laco GS PLoS One; 2011; 6(8):e24314. PubMed ID: 21912628 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of human DNA topoisomerase IB by nonmutagenic ruthenium(II)-based compounds with antitumoral activity. de Camargo MS; da Silva MM; Correa RS; Vieira SD; Castelli S; D'Anessa I; De Grandis R; Varanda E; Deflon VM; Desideri A; Batista AA Metallomics; 2016 Feb; 8(2):179-92. PubMed ID: 26758075 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505. Montaudon D; Palle K; Rivory LP; Robert J; Douat-Casassus C; Quideau S; Bjornsti MA; Pourquier P J Biol Chem; 2007 May; 282(19):14403-12. PubMed ID: 17355975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]